Business Context and Reporting Period
This Form 8-K is a current report filed by Oncocyte Corporation (not Insight Molecular Diagnostics Inc.) on September 20, 2021. The registrant is a California corporation with its principal executive offices in Irvine, California. The filing is intended to disclose a specific corporate event rather than periodic financial results.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document serves solely to announce a corporate event and incorporates a press release by reference.
Material Changes
There are no material financial changes reported in this document. The primary event disclosed is the oral presentation of new data regarding the company's DetermaIO™ immunotherapy response test at the European Society for Medical Oncology (ESMO) annual meeting.
Guidance, Outlook, and Risks
- Management Commentary: The company highlighted the presentation of new clinical data for its DetermaIO™ test.
- Forward-Looking Statements: The filing includes a standard disclaimer that statements containing words such as "may," "will," "believes," or "expects" are forward-looking. Actual results may differ materially due to risks detailed in the company's Form 10-K.
- Emerging Growth Company Status: Oncocyte Corporation has elected to be classified as an emerging growth company.
Investor Verification Checklist
- Verify the specific clinical data presented for DetermaIO™ in the attached press release (Exhibit 99.1).
- Review the company's most recent Form 10-K for detailed risk factors and financial position, as this 8-K contains no financial metrics.
- Confirm the trading symbol OCX on The Nasdaq Stock Market LLC.
- Note that the filing date is September 20, 2021, and assess the current relevance of the data presented.